U Ganswindt
Overview
Explore the profile of U Ganswindt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
186
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zamboglou C, Aebersold D, Albrecht C, Boehmer D, Ganswindt U, Schmidt-Hegemann N, et al.
Strahlenther Onkol
. 2024 Aug;
201(1):4-10.
PMID: 39196366
A significant number of prostate cancer patients are long-term survivors after primary definitive therapy, and the occurrence of late side effects, such as second primary cancers, has gained interest. The...
2.
Koerber S, Hocht S, Aebersold D, Albrecht C, Boehmer D, Ganswindt U, et al.
Strahlenther Onkol
. 2024 Jan;
200(3):181-187.
PMID: 38273135
For prostate cancer, the role of elective nodal irradiation (ENI) for cN0 or pN0 patients has been under discussion for years. Considering the recent publications of randomized controlled trials, the...
3.
Arnold C, Lindner A, Schachtner G, Tulchiner G, Tulchiner N, Mangesius J, et al.
Strahlenther Onkol
. 2021 Aug;
198(1):25-32.
PMID: 34414475
Purpose: Treatment of muscle-invasive bladder cancer (MIBC) remains challenging, especially for elderly and/or comorbid patients. Patients who are unfit for or refuse surgery should receive bladder-preserving multimodality treatment (BPMT), consisting...
4.
Karl A, Buchner A, Tympner C, Kirchner T, Ganswindt U, Belka C, et al.
World J Urol
. 2020 Feb;
38(6):1587-1588.
PMID: 32076820
In multivariate analysis, GS of the regular prostatectomy specimen was the only statistically significant parameter for pT2R1 prostate cancer.
5.
Carl G, Reitz D, Schonecker S, Pazos M, Freislederer P, Reiner M, et al.
Technol Cancer Res Treat
. 2018 Nov;
17:1533033818806002.
PMID: 30453842
Purpose/objective: Reproducible patient positioning remains one of the major challenges in modern radiation therapy. Recently, optical surface scanners have been introduced into clinical practice in addition to well-established positioning systems,...
6.
Reitz D, Carl G, Schonecker S, Pazos M, Freislederer P, Niyazi M, et al.
Radiat Oncol
. 2018 Jul;
13(1):128.
PMID: 30012156
Background: Intra-fraction motion represents a crucial issue in the era of precise radiotherapy in several settings, including breast irradiation. To date, only few data exist on real-time measured intra-fraction motion...
7.
Schmidt-Hegemann N, Li M, Eze C, Belka C, Ganswindt U
Urologe A
. 2017 Oct;
56(11):1402-1409.
PMID: 28983664
The risk classification for localized prostate cancer is based on the groups "low", "intermediate", and "high-risk" prostate cancer. Following this established risk group definition, locally advanced prostate cancer (cT3/4N0M0) has...
8.
Wendt T, Gademann G, Pambor C, von Specht H, Martin T, Baltas D, et al.
Strahlenther Onkol
. 2016 May;
180 Suppl 1:5-87.
PMID: 27137922
No abstract available.
9.
Tritschler S, Ganswindt U, Stief C
Urologe A
. 2016 Feb;
55(3):318-25.
PMID: 26873385
Background: National and international guidelines recommend radical prostatectomy (RP) and radiotherapy (EBRT) as standard treatment for intermediate- and high-risk prostate cancer. Survival benefit of RP in prostate cancer has been...
10.
Schmid S, Landry G, Thieke C, Verhaegen F, Ganswindt U, Belka C, et al.
Phys Med Biol
. 2015 Nov;
60(24):9329-47.
PMID: 26581022
Proton range verification based on prompt gamma imaging is increasingly considered in proton therapy. Tissue heterogeneity normal to the beam direction or near the end of range may considerably degrade...